EUCTR2009-013066-31-IT进行中（未招募）不适用
?Levosimendan to reduce mortality in high risk cardiac surgery patients. A multicentre randomized controlled trial.? - ND
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 个研究点开始时间: 2009年6月11日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-conseso informato scritto
- •-eta` superiore ai 18 anni
- •-disfunzione miocardica perioperatoria definita sindrome da bassa gittata etc.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •trapianto del rene o del fegato; -previous unusual response to levosimendan or soluvit or any of their components
- •-inclusion in other randomised controlled studies in the previous 30 days
- •-levosimendan administration in the previous 30 days
- •-Parkinson?s desease
- •-emergency operation
- •-Kidney or liver transplant
- •-Liver cirrhosis (Child B or C)
- •-decision to use ECMO (ECMO already started or planned)
- •-do not resuscitate patient
研究者
相似试验
已完成
4 期
Levosimendan in High Risk Patients Undergoing Cardiac SurgeryLow Cardiac Output SyndromeNCT00994825Università Vita-Salute San Raffaele1,000
招募中
3 期
Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) an international randomized phase III trial10006291breast cancerNL-OMON56057ederlands Kanker Instituut94
招募中
3 期
Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trialbreast cancer2024-516196-32-00Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting172
招募中
3 期
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic ShockCardiogenic ShockNCT04020263Pr Bruno LEVY610
未知
不适用
REDUCING EARLY MORTALITY AND EARLY MORBIDITY BY EMPIRIC TUBERCULOSIS TREATMENT REGIMENS (REMEMBER)PER-030-11El Instituto Nacional de Alergia y Enfermedades Infecciosas (NIAID) de los Estados Unidos,